Form 144 TANGO THERAPEUTICS For: 18 November By Investing.com
This article from Investing.com announces a Form 144 filing for Tango Therapeutics (TNGX) on November 18, 2026. Form 144 filings indicate an intent to sell restricted securities, which can be of interest to investors monitoring insider transactions. The brief report highlights the company and the filing date without providing further details on the nature or volume of the proposed sale.
Director John Ketchum proposes selling 7,590 shares of Tango Therapeutics (TNGX).
John Ketchum, a director of Tango Therapeutics, Inc. (TNGX), has filed a notice for a proposed sale of 7,590 common shares, valued at approximately $183,450.30, with an approximate sale date of November 17, 2026. These shares were acquired through restricted stock unit vesting between August 2024 and August 2026. This transaction is being conducted under Rule 10b5-1, with the plan adoption date listed as August 18, 2026.
Warrants in a fund's Tango Therapeutics (TNGX) stake carry a 9.99% ownership limit on exercise.
TCG Crossover Fund II, L.P., its general partner TCG Crossover GP II, LLC, and Chen Yu have reported a 4.6% beneficial ownership stake in Tango Therapeutics (TNGX), totaling 7,839,709 shares. This stake includes common shares and pre-funded warrants exercisable within 60 days. A key provision limits the exercise of these warrants, preventing the holder and affiliates from beneficially owning more than 9.99% of TNGX shares immediately after exercise.
3.99 million pre-funded warrants figure in Farallon's Tango Therapeutics (TNGX) stake.
Farallon Capital Management, L.L.C. has reported an amended 4.9% beneficial ownership stake in Tango Therapeutics, Inc. (TNGX) as of September 30, 2026. This stake, totaling 8,543,875 shares, includes 4,550,688 common shares and 3,993,187 pre-funded warrants. The warrants are exercisable for one share each, assuming they can be exercised within 60 days and do not exceed a 9.99% beneficial ownership limitation.
Tango Therapeutics R&D president Adam Crystal sells $125,000 in stock
Adam Crystal, President of Research & Development at Tango Therapeutics (NASDAQ:TNGX), sold 5,000 shares of company stock for $125,000 on November 11, 2026. This transaction occurred under a Rule 10b5-1 trading plan after the company's stock surged over 212% in the past year. Crystal also exercised options to acquire 5,000 shares prior to the sale.
Tango Therapeutics (TNGX) executive exercises $2.91 options, then sells the 5,000 shares.
Crystal Adam, President of R&D at Tango Therapeutics (TNGX), exercised options to acquire 5,000 common shares at $2.91 each on November 11, 2026. Subsequently, she sold these 5,000 shares at a weighted average price of $25.00 per share, with sale prices ranging from $25.00 to $25.9999. These transactions were executed under a Rule 10b5-1 trading plan established on June 10, 2026.
Form 4 Tango Therapeutics Inc: Adam Crystal (President, R&D) For: 11 November
This article reports on a Form 4 filing for Tango Therapeutics Inc., specifically detailing an action involving Adam Crystal, the President of R&D. The filing is dated for November 11. The article itself was published on November 13, 2026, at 07:06 p.m.
Tango Therapeutics Stock Has The Bull Case Changed After JPMorgan Backing
Tango Therapeutics reported a significant net loss in Q3 2026 and for the nine months, emphasizing its reliance on external funding. The company is advancing its precision oncology pipeline, particularly a new Phase 1/2 combination trial for vopimetostat, which deepens its focus on MTAP-driven tumor biology. Despite increased losses, the expanded vopimetostat footprint creates more operational levers for future catalysts, though it also raises execution risk due to a larger clinical workload while the company remains loss-making.
TNGX: Frontline pancreatic Phase III is planned for H1 2027 after encouraging combination data
Tango Therapeutics (TNGX) reported an 82% response rate in 22 pancreatic cancer patients from updated combination data, showing durable responses and favorable tolerability. Following these encouraging results, the company plans to initiate a frontline Phase III study in the first half of 2027. Additionally, a second-line strategy and NSCLC development are highlighted as key upcoming milestones for TNGX.
JP Morgan maintains Tango Therapeutics at Overweight, raises price target to $47 from $46
JP Morgan has maintained its "Overweight" rating for Tango Therapeutics (TNGX) and increased its price target to $47 from $46, indicating a potential upside of 106.7% from its previous closing price. This adjustment follows recent analyst actions on the company, with price targets ranging from $40 to $67 over the last 30 days.
Jefferies raises Tango Therapeutics stock price target on trial data
Jefferies has increased its price target for Tango Therapeutics (NASDAQ:TNGX) from $60 to $65, maintaining a Buy rating, following positive efficacy data from the company's ESMO'26 update for MTAP-deleted pancreatic ductal adenocarcinoma. The firm noted a confirmed overall response rate of approximately 79% and strong progression-free survival data, supporting future pivotal trials. Other analysts from Stifel, Wedbush, JPMorgan, and William Blair have also raised their price targets or initiated positive coverage on Tango Therapeutics, reflecting widespread bullish sentiment.
HC Wainwright & Co. maintains Tango Therapeutics at Buy, lowers price target to $67 from $68
HC Wainwright & Co. has reiterated its "Buy" rating for Tango Therapeutics (TNGX) but slightly reduced its price target from $68 to $67, a 1.5% decrease. The new price target suggests a potential upside of 194.6% from the stock's closing price of $22.74 on November 9th. This update provides investors with a revised outlook on Tango Therapeutics' stock performance.
JPMorgan raises Tango Therapeutics price target to $47 on pipeline
JPMorgan has raised its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) to $47 from $46, maintaining an Overweight rating, driven by expected near-term updates on its pipeline, particularly for 456 monotherapy and vopi monotherapy in January. The firm sees significant potential in Tango Therapeutics' combination work for pancreatic ductal adenocarcinoma and expansion into other tumor types. Despite the company remaining unprofitable, analysts express growing optimism, with several firms also recently increasing their price targets for TNGX.
Tango Therapeutics Reports Q3 2026 Net Loss of $68.4 Million
Tango Therapeutics reported a net loss of $68.4 million in Q3 2026, a significant drop from net income of $15.9 million in the prior year, primarily due to increased operating expenses and zero collaboration revenue. Despite the financial loss, the company announced promising Phase 1/2 results for vopimetostat combined with daraxonrasib in pancreatic cancer and outlined plans for a global Phase 3 trial. Tango Therapeutics ended the quarter with $977.5 million in cash, cash equivalents, and marketable securities.
TNGX: Promising pancreatic cancer data support a planned Phase 3 trial, with $977.5M in cash and securities
Tango Therapeutics (TNGX) reported promising data for its pancreatic cancer combination treatment, showing an 82% overall response rate (ORR) and 88% 9-month progression-free survival (PFS) in second-line/third-line patients. These results support a planned front-line Phase 3 trial in the first half of 2027. The company maintains a strong financial position with $977.5 million in cash and marketable securities, despite a Q3 net loss of $68.4 million.
Collaboration revenue hits $0 as Tango Therapeutics (TNGX) swings to a quarterly loss.
Tango Therapeutics (TNGX) reported a significant net loss of $68.4 million for Q3 2026, a swing from a $15.9 million net income in the prior year, primarily due to collaboration revenue dropping to $0 after recognizing deferred revenue from Gilead in 2025. Despite the loss, the company has $977.5 million in cash, cash equivalents, and marketable securities, projected to fund operations for at least 12 months. Tango is reprioritizing its R&D efforts on PRMT5 therapies, vopimetostat, and TNG456, and plans to initiate a global, randomized registrational trial for vopimetostat in first-line PDAC in the first half of 2027, following promising clinical data.
Cancer Trial Start Could Be A Big Moment For Tango Therapeutics Stock
Tango Therapeutics has initiated a Phase 1/2 clinical trial for its PRMT5 inhibitor vopimetostat, combined with Erasca's ERAS-0015, in MTAP deleted pancreatic and non-small cell lung cancers. This trial is significant as it expands Tango's focus on MTAP deleted solid tumors and could influence its investment narrative, which is largely centered on vopimetostat combinations. The company's future revenue and earnings projections are tied to the success of this and other vopimetostat trials.
Tango Therapeutics, Inc. (TNGX) Misses Q3 EPS by 4c
Tango Therapeutics, Inc. (TNGX) reported a Q3 EPS of ($0.39), falling short of analyst estimates by $0.04. The company's revenue growth percentage was -100.0%. This news provides financial updates for serious traders following TNGX.
Tango Therapeutics, Inc. (TNGX) latest stock news and headlines
This article provides a compilation of recent news and headlines concerning Tango Therapeutics, Inc. (TNGX). It includes financial results, updates on clinical trials for their PRMT5 inhibitor Vopimetostat, conference participations, and analyst coverage. The stock performance shows TNGX with significant year-to-date and one-year returns, despite some recent stock falls following trial data.
Tango Therapeutics 3Q 2026: Revenue $0, EPS ($0.39) — 10-Q Summary
Tango Therapeutics reported no collaboration revenue in 3Q 2026, a significant drop from $53.8 million a year earlier, leading to a net loss of $68.39 million and a diluted EPS of ($0.39). The company plans to initiate a global registrational trial for vopimetostat plus daraxonrasib in early 2027 and is refocusing its pipeline on PRMT5 therapies, vopimetostat, and TNG456, while also reducing its workforce by approximately 14%.
TNGX: Tango Therapeutics Inc. filed SEC Form 8-K: Results of...
Tango Therapeutics Inc. reported a Q3 2026 net loss of $68.4 million ($0.39 per share), a significant shift from a $15.9 million profit a year ago, primarily due to zero collaboration revenue after the Gilead partnership ended. Despite increased R&D and G&A expenses, the company maintains a strong cash position of $977.5 million, providing substantial funding for its ongoing clinical trials.
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics reported its third-quarter 2026 financial results, highlighting significant progress in its clinical pipeline, particularly for vopimetostat in pancreatic cancer. The company presented promising Phase 1/2 data for vopimetostat in combination with daraxonrasib, showing an 82% objective response rate and 88% 9-month progression-free survival in pancreatic cancer patients. Based on these results, Tango plans to initiate a registrational Phase 3 study in the first half of 2027 and explore accelerated approval for its combination therapy in second-line pancreatic cancer.
Tango Therapeutics, Inc. (TNGX) Seasonal returns chart
This article provides a seasonal returns chart for Tango Therapeutics, Inc. (TNGX), showing the average monthly price return from 2020 to 2026. As of the close on November 6th, 2026, TNGX was trading at $21.50, up 3.02% for the day.
Tango Therapeutics president sells $112,107 in shares By Investing.com
Adam Crystal, President of Research & Development at Tango Therapeutics, sold 5,000 shares of the company's common stock for $112,107 on November 2, 2026, as part of a pre-arranged trading plan. Prior to the sale, he exercised options to acquire the same number of shares. This transaction comes amidst positive analyst coverage and raised price targets for Tango Therapeutics, following recent trial data and financial results.
Tango Therapeutics, Inc. (TNGX) stock price, news, quote and history
Tango Therapeutics, Inc. (TNGX) stock is currently trading at $24.35, down 12.82%, with market data experiencing temporary delays. The company, a precision oncology firm, is developing several drugs for various cancers, including TNG462 for pancreatic and lung cancer, and TNG260 for lung cancer. Recent news includes positive cancer trial data, expansion of biotech research coverage, and updates on development strategy.
Form 4 Tango Therapeutics Inc: Adam Crystal (President, R&D) For: 2 November By Investing.com
This article reports on a Form 4 filing for Tango Therapeutics Inc, specifically detailing an insider transaction involving Adam Crystal, the President of Research & Development, on November 2nd. The filing indicates a significant event concerning an executive at the company. The article itself is brief, primarily serving as an announcement of the filing rather than an in-depth analysis.
Tango Therapeutics president sells $112,107 in shares
Adam Crystal, President of Research & Development at Tango Therapeutics, sold 5,000 shares of the company's common stock for $112,107 on November 2, 2026, as part of a pre-arranged trading plan. Prior to this, he exercised options to acquire 5,000 shares for $14,550. Analysts have recently issued positive updates on Tango Therapeutics, raising price targets based on trial data and financial results.
A $2.91 option exercise accompanies Tango Therapeutics (TNGX) R&D president’s 5,000-share sale.
Crystal Adam, President of R&D at Tango Therapeutics (TNGX), exercised options for 5,000 common shares at an exercise price of $2.91 on November 2, 2026. On the same date, Adam sold a total of 5,000 shares in two separate transactions at weighted average prices of $22.2617 and $22.9882 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on June 10, 2026.
Sales of 5,571 and 1,460 shares at Tango Therapeutics (TNGX) follow a prearranged trading plan.
Jessica Newcomb, Principal Accounting Officer at Tango Therapeutics (TNGX), sold 5,571 common shares at $22.2774 and 1,460 common shares at $22.9816 on November 2, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted on June 23, 2026. Following these sales, Newcomb's direct holdings in common stock total 52,090 shares, including 43,666 unvested restricted stock units.
Form 4 Tango Therapeutics, Inc. For: Nov 02 Filed by: Newcomb Jessica
Jessica Newcomb, Principal Accounting Officer at Tango Therapeutics, Inc. (TNGX), filed a Form 4 detailing transactions on November 2, 2026. She disposed of 5,571 shares of common stock at a weighted average price of $22.2774 and another 1,460 shares at $22.9816, pursuant to a Rule 10b5-1 trading plan. Following these transactions, Newcomb beneficially owns 52,090 shares, including 43,666 unvested restricted stock units.
Form 4 Tango Therapeutics Inc: Jessica Newcomb (Principal Accounting Officer) For: 2 November
This article reports on a Form 4 filing from Tango Therapeutics Inc., detailing insider transactions by Jessica Newcomb, the Principal Accounting Officer, for November 2. The filing indicates a change in her holdings, which is standard regulatory disclosure for company insiders.
A CEO's conference chat will be shown live online, then archived for 90 days.
Tango Therapeutics (NASDAQ: TNGX) announced its President and CEO, Malte Peters, will participate in a fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 8:00 AM EST. A live webcast of the event will be available on the company’s website, with a replay archived for 90 days. The announcement also highlighted Tango Therapeutics' focus as a clinical-stage biotechnology company developing targeted therapies for cancer.
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
Tango Therapeutics and Erasca, Inc. have initiated a Phase 1/2 study of their oral PRMT5 inhibitor vopimetostat in combination with the pan-RAS molecular glue ERAS-0015. This study will evaluate the combination in patients with MTAP-deleted pancreatic ductal adenocarcinoma and MTAP-deleted/RAS-mutant non-small cell lung cancer. Both companies are optimistic about the synergistic potential of this dual-targeted approach for difficult-to-treat cancers.
Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
Tango Therapeutics (NASDAQ: TNGX) announced that its President and CEO, Malte Peters, M.D., will participate in a fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 8:00 AM EST. A live webcast and replay of the event will be available on the company's website. Tango Therapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for cancer.
Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
Tango Therapeutics (NASDAQ: TNGX) announced that its President and CEO, Malte Peters, M.D., will participate in a fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference on November 10, 2026. The event will be webcast live and archived on the company's website. Tango Therapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for cancer patients.
Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
Tango Therapeutics, Inc. announced that its President and CEO, Malte Peters, M.D., will participate in a fireside chat at Guggenheim's 3rd Annual Healthcare Innovation Conference on November 10, 2026. A live webcast of the event will be available on the company's investor relations website, with a replay archived for 90 days. Tango Therapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for cancer.
Tango Therapeutics, Inc. (TNGX) Seasonal returns chart
This article provides a historical seasonality chart for Tango Therapeutics, Inc. (TNGX), displaying the average monthly price return between 2020 and 2026. The data shows the stock's performance trends at market close on November 3, 2026, and after-hours trading.
A 20,000-share sale is planned by Tango Therapeutics (TNGX) officer Adam Crystal.
Tango Therapeutics (TNGX) officer Adam Crystal plans to sell 20,000 common shares worth $454,400 on November 2, 2026, which he will receive through stock-option exercises. This planned sale follows three previous 10b5-1 sales of 27,000 shares each on August 3, September 1, and October 1, 2026. The SEC Form 144 filing provides details on the transaction and associated figures.
Trial Results Could Be A Game Changer For Tango Therapeutics (TNGX)
Tango Therapeutics (TNGX) reported updated Phase 1/2 data showing promising objective response and disease control rates for vopimetostat plus RAS(ON) inhibitors in MTAP-deleted, RAS-mutant pancreatic and lung cancers. The decision to advance vopimetostat into a global randomized registrational trial for front-line MTAP-deleted pancreatic cancer indicates a significant commitment, potentially shifting the company's investment narrative. While the data is encouraging, the primary risk lies in whether these positive results will translate into larger, controlled settings.
Why Tango Therapeutics (TNGX) Is Back In The Spotlight
Tango Therapeutics (TNGX) has gained attention after reporting positive Phase 1/2 data for vopimetostat combinations in pancreatic cancer and NSCLC, with plans for a global front-line pancreatic cancer trial. Despite recent share price cooling, the stock has seen a significant year-to-date return of 154.31% and analysts consider it undervalued compared to its fair value estimate of $47.09. However, the company's future hinges on the success of late-stage trials for vopimetostat, particularly in challenging indications like pancreatic cancer.
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $68
H.C. Wainwright has reiterated its Buy rating on Tango Therapeutics (TNGX.US) and maintained its target price at $68. This indicates a continued positive outlook from the analyst firm on the company's stock performance and future prospects.
HC Wainwright & Co. maintains Tango Therapeutics at Buy, keeps price target at $68
HC Wainwright & Co. has reiterated its Buy rating for Tango Therapeutics (TNGX), maintaining a price target of $68. This target suggests a potential upside of 205.9% from the stock's closing price of $22.23 on October 28. Investors can find more detailed price target data and analyst recommendations for Tango Therapeutics on the Forecasts tab and News Flow section.
Tango Therapeutics, Inc. (TNGX) stock price, news, quote and history
Tango Therapeutics, Inc. (TNGX) is a precision oncology company focused on developing drugs for unmet medical needs. The company's stock shows significant year-to-date and 1-year returns of 154.29% and 187.74%, respectively, with an average analyst target price of $47.09. Tango Therapeutics is currently developing several drug candidates, including PRMT5 inhibitors and a STK11 loss-of-function mutation inhibitor, with some already in Phase 1/2 clinical trials.
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Tango Therapeutics (TNGX) shares dropped 16.4% after updated phase I/II study data for its pancreatic cancer treatment showed a reduced objective response rate (ORR) of 82%, down from 92%. Despite the fall, the data still indicated durable disease control with an 88% progression-free survival rate at nine months. The company also announced a strategic reprioritization of its R&D programs, including a 14% workforce reduction and discontinuation of certain preclinical activities.
Stifel raises Tango Therapeutics stock price target on trial data
Stifel has increased its price target for Tango Therapeutics (NASDAQ:TNGX) from $40 to $55, maintaining a Buy rating, due to updated trial data for vopimetostat. The company plans a Phase 3 trial for pancreatic cancer and is refocusing on key therapies, leading to a workforce reduction. Despite the bullish outlook, InvestingPro suggests the stock may be overvalued.
Tango Therapeutics, Inc. (TNGX) Options Chain - Yahoo Finance
This page from Yahoo Finance displays the options chain for Tango Therapeutics, Inc. (TNGX). It shows the stock's real-time price, recent performance, and indicates that there are no calls or puts available for the Dec 17, 2027 expiration date. The data is delayed by 15 minutes.
Tango Therapeutics Files 8-K on Vopimetostat Phase 1/2 Trial Update
Tango Therapeutics reported promising results from its Phase 1/2 trial of vopimetostat combined with daraxonrasib for MTAP-deleted, RAS-mutant metastatic pancreatic cancer, showing an 82% objective response rate in pretreated patients. The trial also demonstrated a 100% disease control rate and an 88% 9-month progression-free survival rate, with manageable safety at dose level 1. These findings suggest a significant clinical benefit for a challenging patient population.
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Tango Therapeutics plans to initiate a global Phase III trial in the first half of 2027 for its combination treatment of vopimetostat and daraxonrasib in first-line MTAP-deleted metastatic pancreatic cancer, following promising early-stage results. The Phase I study showed an 82% confirmed objective response rate and 100% disease control rate in previously treated patients, with a manageable safety profile. The company is also exploring an accelerated approval pathway for second-line disease and expanding into MTAP wild-type pancreatic cancer.
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Tango Therapeutics announced plans to initiate a global Phase III trial in the first half of 2027 for vopimetostat combined with daraxonrasib as a first-line treatment for MTAP-deleted metastatic pancreatic cancer, following promising early-stage results. The combination therapy showed an 82% objective response rate and 100% disease control rate in 22 evaluable pancreatic cancer patients, with a generally well-tolerated safety profile. The company is also exploring accelerated approval pathways for second-line pancreatic cancer and expanding into MTAP wild-type disease.
Tango Therapeutics, Inc. (TNGX) Options Chain
This article provides the options chain for Tango Therapeutics, Inc. (TNGX), showing real-time price data and options details. As of October 23, TNGX closed at $23.34, down 16.43%, and was up 2.06% in after-hours trading. The options chain, however, indicates no calls or puts currently available.